Introduction {#S1}
============

Glutamate is the predominant excitatory neurotransmitter in the mammalian CNS and mediates the vast majority of cell-to-cell communication in the brain \[for review, see ([@B1])\]. In addition to being required for millisecond cell-to-cell communication, plasticity of excitatory synaptic transmission likely underlies learning and memory \[for reviews, see ([@B1]--[@B3])\]. Aberrant glutamatergic transmission has been implicated in a wide variety of neurodevelopmental, neurologic, and psychiatric conditions \[for review, see ([@B3])\]. For example, an accumulation of glutamate in the extracellular space and the consequent excessive activation of glutamate receptors likely contributes to the cell death that is observed after acute insults to the nervous system, such as stroke and head trauma \[for review, see ([@B2])\].

Extracellular glutamate is cleared by Na^+^-dependent glutamate transport systems \[for reviews, see ([@B4]--[@B6])\]. In mammals, there are five Na^+^-dependent glutamate transporter gene products; these are called excitatory amino acid transporters (EAAT1-5). EAAT1 (also called GLAST) is found on glia; expression is enriched in cerebellum but also found throughout forebrain ([@B7]). EAAT2 (also called GLT-1) is essentially restricted to astroglia with modest expression by a subset of neurons in hippocampus ([@B7], [@B8]). Results from several different types of studies strongly suggest that GLT-1 and GLAST mediate the bulk of glutamate uptake in the mammalian brain \[([@B9]); for review, see ([@B10])\]. This clearance into astroglia differentiates glutamate from most of the other classical neurotransmitters that are directly recycled back into the presynaptic nerve terminal \[for reviews, see ([@B11], [@B12])\]. These transporters co-transport three Na^+^ ions and one H^+^ with glutamate in the inward direction; the cycle is completed with the counter-transport one K^+^ ion ([@B13]). With this stoichiometry, these transporters are capable of generating up to a one million-fold concentration gradient of glutamate across the plasma membrane \[for review, see ([@B14])\].

The astroglial transporters, GLT-1 and GLAST, are enriched on fine astroglial processes near synapses *in vivo* ([@B15], [@B16]). As might be expected, recent studies suggest that these transporters co-compartmentalize with the enzymes/organelles that would be required to efficiently fuel transport in these spatially restricted domains ([@B17]). For example, GLT-1 or GLAST co-localize with and physically/functionally interact with the Na^+^/K^+^ ATPase ([@B18]). Recently we showed that GLT-1 is part of a co-immunoprecipitable complex with the Na^+^/K^+^-ATPase, most of the glycolytic enzymes, and a subset of mitochondrial proteins ([@B17]). We also demonstrated significant co-localization of GLT-1 with a mitochondrial protein *in vivo* and anatomic overlap of mitochondria with GLT-1 in individual astrocytes in organotypic slice cultures. In a subsequent study, we documented similar interactions and anatomic overlap between GLAST and mitochondrial proteins ([@B19]). In this later study, we measured the percentage of glutamate that is oxidized in astrocytes. We also examined the effect of an inhibitor of glutamate dehydrogenase (GDH), a mitochondrial enzyme that could contribute to glutamate oxidation, on glutamate uptake and found that it inhibited uptake in astrocytes ([@B19]). This effect was not characterized beyond testing of a single concentration of one inhibitor in astrocytes that only express GLAST. In the present study, we characterized the potential effects of inhibitors of GDH on uptake in crude rat brain membranes (P2).

Materials and Methods {#S2}
=====================

Materials {#S2-1}
---------

Adult male Sprague-Dawley rats were obtained from Charles River (Wilmington, MA, USA). All protocols were reviewed and approved by the Institutional Animal Care and Use Committee of the Children's Hospital of Philadelphia (Philadelphia, PA, USA). [l]{.smallcaps}-\[^3^H\]Glu (40--80 Ci/mmol), [d]{.smallcaps}-\[^3^H\]Asp (10--25 Ci/mmol), and γ-amino\[^3^H\]butyric acid (\[^3^H\]GABA; 70--100 Ci/mmol) were obtained from PerkinElmer (Waltham, MA, USA). The specific activity of all ligands was diluted with non-radioactive [l]{.smallcaps}-Glu, [d]{.smallcaps}-Asp, or GABA, respectively (Sigma-Aldrich Co., St. Louis, MO, USA). (−)-Epigallocatechin-monogallate (EGCG; ≥95%, from green tea), hexachlorophene (HCP), bithionol (BTH), Hepes, KCl, CaCl~2~, and K~2~HPO~4~ were obtained from Sigma-Aldrich Co. (St. Louis, MO, USA). Tris base, Tris HCl, NaCl, MgCl~2~, dextrose, and sucrose were obtained from Fisher Scientific (Pittsburgh, PA, USA). Tween-20 was obtained from Bio-Rad (Hercules, CA, USA).

Membrane preparations {#S2-2}
---------------------

Crude membranes (P2) were prepared from cortex and cerebellum as previously described ([@B20]). The preparation is commonly referred to as "crude synaptosomal membranes." In the current paper, we refer to this preparation as crude membranes (P2) to avoid giving the impression that it contains strictly neuronal elements. Cortex or cerebellum was dissected on a metal plate cooled to 4°C. All subsequent steps were performed at 4°C. The tissue was homogenized in 20 volumes (wet weight of tissue) of ice-cold 0.32 M sucrose using a Dounce Teflon/glass homogenizer at 400 rpm for seven strokes (tissue homogenate) and centrifuged at 800 × *g* for 10 min. The supernatant (S1) was then centrifuged at 20,000 × *g* for 20 min. In a subset of experiments, the resultant supernatant was collected (S2). The resultant pellet (P2) was resuspended in 40 vols. of sucrose (0.32 M) by vortexing and centrifuged at 20,000 × *g* for 20 min. This washed crude membrane pellet (P2) was resuspended by vortexing in 50 vols. of sucrose (0.32 M) and homogenized (two strokes at 400 rpm). This resulted in a suspension of approximately 30 μg of protein per 50 μl as determined by the Pierce BCA (bicinchoninic acid) protein assay (Thermo Scientific, Rockford, IL, USA).

Western blot analyses {#S2-3}
---------------------

The subcellular fractions were mixed with equal volumes of Laemmli sample buffer. Dual color molecular weight marker (Bio-Rad) and 3 or 10 μg of protein from each fraction were resolved on 10% SDS-polyacrylamide gels, and transferred to immobilon FL polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA, USA) as described previously ([@B17], [@B19]). The PVDF membranes were blocked in TBS-T (50 mM Tris, pH 8.0, 150 mM NaCl, 0.1% Tween-20) containing 5% non-fat dry milk for 1 h at 25°C. The membranes were then probed with the appropriate antibody overnight at 4°C: rabbit anti-GLT-1 (1:5,000; Dr. Rothstein), mouse anti-GLAST (1:50; Miltenyi Biotec, Auburn, CA, USA), mouse anti-*N*-methyl-[d]{.smallcaps}-aspartate (NMDA) receptor subunit 1 (NR1; 1:500; BD Biosciences, San Jose, CA, USA), rat anti-glial fibrillary acidic protein (GFAP; 1:500; Dr. Lee), or goat anti-neurofilament light polypeptide (NF-L; 1:250; Santa Cruz Biotechnology, Santa Cruz, CA, USA). The membranes were then washed with TBS-T containing 1% milk and incubated with the appropriate fluorescently conjugated anti-mouse, anti-rabbit, anti-goat, or anti-rat antibodies (1:10,000; LiCor Biosciences, Lincoln, NE, USA). Blots were scanned using an Odyssey Infrared Imager (LiCor Biosciences). The yield was calculated as the percentage of total immunoreactivity found in a particular fraction divided by the total immunoreactivity found in the tissue homogenate. The enrichment was calculated as the total immunoreactivity found in a particular fraction divided by the total amount of protein found in the fraction; this was normalized to the tissue homogenate. Therefore a number greater than 1 reflects relative enrichment in a fraction compared to homogenate.

Transport assays {#S2-4}
----------------

Sodium-dependent transport of [l]{.smallcaps}-\[^3^H\]Glu, [d]{.smallcaps}-\[^3^H\]Asp, and \[^3^H\]GABA was measured as previously described ([@B20]). Duplicate assays were performed in a final volume of 0.5 ml containing Tris base (5 mM), HEPES (10 mM), NaCl (140 mM), KCl (2.5 mM), CaCl~2~ (1.2 mM), MgCl~2~ (1.2 mM), K~2~HPO~4~ (1.2 mM), dextrose (10 mM), and substrate in the absence or presence of inhibitors (pH = 7.2). In parallel assays, the uptake was measured in the absence of sodium with the substitution of equimolar amounts of choline chloride for NaCl. As HCP and BTH are not readily soluble in aqueous solutions, they were first dissolved in ethanol (HCP) or dimethyl sulfoxide (BTH) as 10 mM stocks. These stocks were diluted such that the same concentration of solvent (0.1% final concentration) was added to each assay; this meant that the highest concentrations of HCP or BTH used in these assays were 10 μM. In all experiments, 0.1% solvent (ethanol or dimethyl sulfoxide) was added to control assays and this concentration had no effect on uptake (data not shown, *n* = 3). EGCG was prepared and diluted in uptake buffer immediately before measuring uptake. All components excluding the crude membranes were combined into 12 mm × 75 mm glass tubes and equilibrated to 37°C. The assay was initiated with the addition of P2 membranes (50 μl) and stopped with 2 ml of ice-cold (4°C) choline-containing buffer after 3 min. For analyses of the effects of pre-incubation with HCP, the assay was initiated with the addition of radioactive substrate to the crude membranes (P2) incubated with HCP. After the addition of cold choline-containing buffer, the assays were filtered onto pre-wetted glass filter paper (FP-100; Brandel, Gaithersburg, MD, USA) using a cell harvester (Brandel, Gaithersburg, MD, USA). Filters were rinsed three times with 2 ml of cold choline-containing buffer. The radioactivity trapped in the membranes was solubilized with 5 ml of Cytoscint ES (MP Biomedicals, Solon, OH, USA) and measured using scintillation spectrometry (Beckman-Coulter Instruments, LS 6500). Sodium-dependent uptake was determined by subtracting the signal in the choline-containing buffer from the signal in the sodium-containing buffer. The total concentration of substrate (radioactive and non-radioactive) was 0.5 μM unless otherwise indicated. The Na^+^-independent signal observed was less than 5% of the total uptake in the presence of sodium.

Data analysis {#S2-5}
-------------

All values reported are the mean ± SEM of at least three independent experiments that were performed on different days. Concentration-response curves were fit to one-site and two-site competition curves, and these fits were compared by *F*-test using Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA). The top of the curves were constrained to 100% (no inhibition), and for all three compounds, the maximal predicted inhibition from the curve fits was essentially 100% (complete inhibition). Kinetic analyses of glutamate transport performed in the absence and presence of HCP were fit by linear regression as Eadie--Hofstee plots. *K*~m~ and *V*~max~ values were compared using one-way ANOVA with a Bonferroni *post hoc* test using InStat (GraphPad Software Inc., La Jolla, CA, USA). The data for [l]{.smallcaps}-\[^3^H\]Glu, [d]{.smallcaps}-\[^3^H\]Asp, and \[^3^H\]GABA uptake in cortex and cerebellum was analyzed using one-way ANOVA with a Bonferroni *post hoc* test using InStat.

Results {#S3}
=======

We recently found that EGCG, a compound extracted from green tea that inhibits GDH ([@B21]), blocks Na^+^-dependent glutamate uptake in astrocytes. EGCG was only tested at a single concentration (1 mM) using a single concentration of glutamate ([@B19]). The goal of the present study was to determine if inhibition of GDH might inhibit Na^+^-dependent glutamate transport in membrane preparations from brain. As astrocytes in culture express GLAST and not GLT-1 ([@B22], [@B23]), we used crude membranes (P2) from cortex to further explore this effect. Genetic deletion of GLT-1 from mice essentially eliminates uptake from crude cortical membrane preparations (P2), and the pharmacology of glutamate uptake in this preparation parallels that observed for GLT-1 ([@B9], [@B20], [@B24]). Although this is classically considered a subcellular fraction that contains nerve terminals, it also contains substantial amounts of astroglial elements ([@B25], [@B26]). We analyzed the subcellular distributions of two different glial glutamate transporters \[GLT-1 and GLAST; ([@B15], [@B16])\], a neuronal receptor \[the NR1 subunit of the NMDA receptor; ([@B1])\], a glial cytoskeletal protein (GFAP), and a neuronal cytoskeletal protein \[NF-L; ([@B27]); see Figure [1](#F1){ref-type="fig"}; Table [1](#T1){ref-type="table"}\]. The yield of both glutamate transporters was about 40% in the cortical P2 fraction and about 60% in the cerebellar P2 fraction, while the yield of NR1 was about 75% in the cortical P2 fraction and only about 40% in the cerebellar P2 fraction. The yields of both cytoskeletal proteins were 10% or less in both the cerebellar and cortical P2 fractions. Together these studies show that the P2 fractions contain glial and neuronal membrane proteins consistent with the earlier studies ([@B25], [@B26]).

![**Analyses of neuronal and astroglial proteins in tissue homogenate (TH) and various subcellular fractions as described in Section "[Materials and Methods](#S2){ref-type="sec"}**." To ensure that signal was in the linear range, 3 μg of protein from each fraction were used for the analyses of GLT-1 or GLAST and 10 μg of protein were for the analyses of the other proteins (NR1 subunit of the NMDA receptor, NR1; GFAP, and NF-L). The western blots shown are all from one animal; these analyses have been reproduced in three additional animals (see Table [1](#T1){ref-type="table"} for data analyses).](fendo-04-00123-g001){#F1}

###### 

**Analyses of neuronal and astroglial proteins in tissue homogenate (TH) and various subcellular fractionations as described in Section "[Materials and Methods](#S2){ref-type="sec"}**."

                   TH    S1    S2            P2                                                  
  ---------------- ----- ----- ------------- ---------- -------------- ----------- ------------- -----------
  **Cortex**                                                                                     
  GLT-1            1.0   100   1.1 ± 0.2     93 ± 20    0.44 ± 0.06    17 ± 2      1.2 ± 0.4     39 ± 13
  GLAST            1.0   100   1.4 ± 0.3     112 ± 23   0.41 ± 0.07    15 ± 3      1.2 ± 0.4     39 ± 12
  NR1              1.0   100   1.3 ± 0.2     107 ± 20   0.14 ± 0.005   5.2 ± 0.1   2.3 ± 0.4     74 ± 14
  GFAP             1.0   100   0.41 ± 0.08   34 ± 7     0.5 ± 0.1      19 ± 4      0.26 ± 0.07   8 ± 2
  NF-L             1.0   100   0.42 ± 0.09   34 ± 7     0.23 ± 0.04    9 ± 1       0.3 ± 0.1     10 ± 3
  **Cerebellum**                                                                                 
  GLT-1            1.0   100   1.3 ± 0.09    100 ± 5    0.4 ± 0.3      13 ± 8      2.7 ± 0.7     67 ± 20
  GLAST            1.0   100   1.4 ± 0.05    108 ± 2    0.7 ± 0.1      22 ± 4      2.4 ± 0.6     59 ± 17
  NR1              1.0   100   0.5 ± 0.2     36 ± 14    0.4 ± 0.3      14 ± 10     1.2 ± 0.1     37 ± 9
  GFAP             1.0   100   0.37 ± 0.05   28 ± 4     0.57 ± 0.08    19 ± 2      0.18 ± 0.02   4.4 ± 0.7
  NF-L             1.0   100   0.36 ± 0.08   27 ± 7     0.7 ± 0.2      24 ± 6      0.09 ± 0.02   2.1 ± 0.3

Enrichment and yield are normalized to the levels of the tissue homogenate as described in Section "[Materials and Methods](#S2){ref-type="sec"}." Data are the mean ± SEM of at least three independent measurements.

In the first set of experiments, the effects of increasing concentrations of EGCG on Na^+^-dependent uptake were examined (Figure [2](#F2){ref-type="fig"}A). The effects of EGCG were concentration-dependent and inhibited uptake with an IC~50~ value of 234 μM. The maximal inhibition observed was 83% at 1 mM; higher concentrations were not tested because of solubility concerns. EGCG inhibits purified GDH with an IC~50~ value of ∼0.5 μM ([@B21], [@B28]), but EGCG is relatively hydrophilic and has limited stability in solution ([@B29]).

![**Concentration-dependence of the effects of GDH inhibitors on of Na^+^-dependent [l]{.smallcaps}-\[^3^H\]-glutamate transport into crude membranes (P2) prepared from cortex**. Transport of [l]{.smallcaps}-\[^3^H\]-glutamate (0.5 μM) was measured in the absence or presence of increasing concentrations of inhibitors, as described in Section "[Materials and Methods](#S2){ref-type="sec"}." The percent of control represents the velocity of transport measured in the presence of inhibitor divided by that observed in the absence of inhibitor multiplied by 100. **(A)** Inhibition by EGCG was fit to a one-site competition model with an IC~50~ value of 234 μM. **(B)** Inhibition by HCP was fit to a two-site competition model. The IC~50~ value for the high affinity component was 30 nM, and the IC~50~ value for the lower affinity component was 14 μM. Based on this fit, 33% of the sites were high affinity and 67% were of lower affinity. **(C)** Inhibition by BTH was fit to a two-site competition model with an IC~50~ for fraction 1 (42%) of 84 nM and an IC~50~ for fraction 2 (58%) of 26 μM. Data are the mean ± SEM of at least three independent measurements (except for incubation of 1 μM BTH, of which there were only two observations).](fendo-04-00123-g002){#F2}

Several other inhibitors of GDH were recently identified in a high-throughput screen ([@B28]). We chose two additional inhibitors of GDH to reduce the likelihood that effects of EGCG on glutamate uptake might be attributed to a non-specific interaction with a target other than GDH. All three of these compounds interact with different sites on GDH ([@B30]). The first compound examined, hexachlorophene (HCP), caused a concentration-dependent inhibition of Na^+^-dependent glutamate uptake (Figure [2](#F2){ref-type="fig"}B). When these data were fit to a single site, the IC~50~ value was 3.9 μM, but the inhibition data were best fit to two sites with IC~50~ values of 30 nM and 14 μM. The maximal inhibition observed was 70% at 10 μM, and higher concentrations were not tested to avoid effects of solvent on uptake. The reported IC~50~ value for inhibition of GDH is 1.7 μM ([@B28]). We also examined the effects of bithionol (BTH), which caused a concentration-dependent inhibition of Na^+^-dependent glutamate transport activity in crude cortical membranes (P2; Figure [2](#F2){ref-type="fig"}C). The IC~50~ value was 4.1 μM when the data were fit to a single site, but the inhibition data were best fit to two sites with IC~50~ values of 84 nM and 26 μM. The maximal inhibition observed was 60% at 10 μM, and higher concentrations were not tested to avoid effects of solvent on uptake. The reported IC~50~ value for inhibition of GDH is 5.5 μM ([@B28]). Together, these studies show that three different inhibitors of GDH also inhibit Na^+^-dependent glutamate uptake in crude cortical membranes (P2).

One might expect that the effects of inhibition of GDH would increase with pre-incubation. To address this possibility, crude cortical membranes (P2) were pre-incubated with 6.0 μM HCP for up to 15 min prior to initiation of uptake by the addition of [l]{.smallcaps}-\[^3^H\]Glu. Somewhat surprisingly, the amount of inhibition observed with pre-incubations of 1, 3, 5, 10, and 15 min was not significantly different than that observed with no pre-incubation (Figure [3](#F3){ref-type="fig"}). In these experiments, the crude membranes (P2) were warmed to 37°C for the same amount of time, regardless of the length of the pre-incubation with HCP, to ensure the effects seen were independent of the increased time that the crude membranes (P2) were warmed to 37°C. This shows that the effects of HCP on glutamate uptake are very rapid and essentially instantaneous in this experimental paradigm where uptake is measured for 3 min.

![**Effects of pre-incubation with HCP (6 μM) on Na^+^-dependent [l]{.smallcaps}-\[^3^H\]-glutamate transport into crude membranes (P2) prepared from cortex**. HCP (or vehicle) was added to crude membranes (P2) at 37°C at 1, 3, 5, 10, or 15 min prior to the initiation of transport with the addition of [l]{.smallcaps}-\[^3^H\]-glutamate, or simultaneously with [l]{.smallcaps}-\[^3^H\]-glutamate (time = 0 min). Percent of control represents the velocity of transport in the presence of inhibitor divided by that observed in the absence of inhibitor multiplied by 100. Data are the mean ± SEM of at least three independent measurements.](fendo-04-00123-g003){#F3}

To further characterize the mechanism of action, we examined the effects of HCP on the concentration-dependence for [l]{.smallcaps}-\[^3^H\]-Glu uptake. As was previously observed by us and others \[for review, see ([@B31])\], the *K*~m~ for [l]{.smallcaps}-\[^3^H\]-Glu uptake was ∼5 μM and the *V*~max~ was ∼1.2 nmol/mg/min. HCP had no effect on the *K*~m~ value and decreased the *V*~max~ for [l]{.smallcaps}-\[^3^H\]-glutamate uptake (Figure [4](#F4){ref-type="fig"}). These data are consistent with a non-competitive mechanism of inhibition of glutamate uptake.

![**Eadie--Hofstee plot of the concentration-dependence of [l]{.smallcaps}-\[^3^H\]-glutamate transport in crude membranes (P2) prepared from cortex with no treatment (control; circle), 0.1 μM HCP (square), or 6.0 μM HCP (triangle)**. Uptake was determined as described in Section "[Materials and Methods](#S2){ref-type="sec"}." Data presented are from a single experiment that has been repeated in four independent experiments with similar results. The *K*~m~ values for transport were 5.7 ± 0.3 μM in vehicle control, 5.4 ± 0.4 μM in the presence of 0.1 μM HCP, and 4.2 ± 1.0 μM in the presence of 6.0 μM HCP. The *V*~max~ values for transport were 1.6 ± 0.4 (nmol/mg protein/min) for vehicle control, 1.2 ± 0.4 in the presence of 0.1 μM HCP, and 0.7 ± 0.1 in the presence of 6.0 μM HCP. The *K*~m~ or *V*~max~ values were normalized to vehicle controls for each experiment (set to 100%) and compared to those observed in the presence of HCP. HCP had no significant effect on *K*~m~ value, but significantly reduced the *V*~max~ value at either 0.1 μM (*p* \< 0.01) or 6 μM (*p* \< 0.001).](fendo-04-00123-g004){#F4}

Na^+^-dependent glutamate uptake into crude cerebellar membranes (P2) displays a dramatically different pharmacology from that observed in crude cortical membranes \[P2; ([@B20], [@B32])\]. In fact, the pharmacology of transport in crude cerebellar membranes (P2) is consistent with that of GLAST ([@B24]). To determine if the effects of inhibition of GDH are selective for these two different transport activities, we compared the effects of HCP, EGCG, and BTH on Na^+^-dependent glutamate uptake in crude membranes (P2) prepared from cortex and cerebellum. None of the GDH inhibitors had any effect on Na^+^-dependent uptake in crude membranes (P2) prepared from cerebellum (Figure [5](#F5){ref-type="fig"}A).

![**Effects of EGCG (300 μM), HCP (6 μM), or BTH (3 μM) on Na^+^-dependent transport of L-glutamate (A), D-aspartate (B), or GABA (C) measured in crude membranes (P2) prepared from cortex (open bars) or cerebellum (shaded bars)**. Transport of all three substrates in both brain regions was measured in parallel experiments with different vehicle controls as described in the Section "[Materials and Methods](#S2){ref-type="sec"}." Data are the mean ± SEM from at least three independent experiments. Data were compared to vehicle controls by ANOVA. \*Indicates a *p* \< 0.05, \*\* indicates a *p* \< 0.01, and \*\*\* indicates a *p* \< 0.001.](fendo-04-00123-g005){#F5}

[d]{.smallcaps}-Aspartate is transported by the Na^+^-dependent glutamate transporters ([@B5]), but is not a substrate for GDH ([@B33]). To determine if the effects of the GDH inhibitors might be related to direct metabolism of the glutamate that moves through the transporter during uptake, we examined the effects of the three different GDH inhibitors on [d]{.smallcaps}-\[^3^H\]-Asp uptake in crude membranes (P2) prepared from cortex and cerebellum. As was observed with [l]{.smallcaps}-\[^3^H\]-Glu transport, all three compounds inhibited [d]{.smallcaps}-\[^3^H\]-Asp uptake in crude cortical membranes (P2), and no effects were observed in cerebellar membranes (P2; Figure [5](#F5){ref-type="fig"}B).

The inhibitory neurotransmitter, γ-aminobutyric acid (GABA), is also cleared by Na^+^-dependent transport systems. The role of GDH in GABA metabolism is unclear, but it may play a role in the deamination of glutamate formed from the transamination of GABA by GABA-transaminase, also found in mitochondria \[for discussions, see ([@B34], [@B35])\]. Therefore, the effects of the three different GDH inhibitors on Na^+^-dependent \[^3^H\]-GABA transport were examined in crude membranes (P2) prepared from cortex and cerebellum. As was observed with [l]{.smallcaps}-\[^3^H\]-Glu or [d]{.smallcaps}-\[^3^H\]-Asp, all three GDH inhibitors reduced Na^+^-dependent \[^3^H\]-GABA transport in cortical membranes (P2; Figure [5](#F5){ref-type="fig"}C). However, in contrast to the lack of inhibition observed with [l]{.smallcaps}-\[^3^H\]-Glu or [d]{.smallcaps}-\[^3^H\]-Asp, all three compounds also inhibited \[^3^H\]-GABA transport in crude cerebellar membranes (P2).

Discussion {#S4}
==========

In a recent study, we obtained preliminary evidence that inhibition of GDH might lead to inhibition of Na^+^-dependent glutamate uptake ([@B19]). In the present study, we observed concentration-dependent inhibition of Na^+^-dependent glutamate uptake in crude membranes (P2) prepared from cortical tissue using three different inhibitors of GDH. The effects of one of these inhibitors, HCP, were studied further. As pre-incubation did not increase the effects of HCP, inhibition occurs relatively rapidly (within seconds to minutes). HCP had no effect on *K*~m~ for glutamate uptake, but reduced *V*~max~, consistent with a non-competitive mechanism of action. All three compounds also inhibited Na^+^-dependent [d]{.smallcaps}-\[^3^H\]-Asp and \[^3^H\]-GABA to a similar extent in crude cortical membranes (P2). However, in crude membranes (P2) prepared from cerebellum, these compounds did not affect Na^+^-dependent [l]{.smallcaps}-\[^3^H\]-Glu or [d]{.smallcaps}-\[^3^H\]-Asp, but did inhibit \[^3^H\]-GABA transport.

The fact that three different inhibitors of GDH also block Na^+^-dependent glutamate and GABA uptake suggests that the observed inhibition is likely to be due to an effect on GDH. The potencies of HCP or BTH for inhibition of glutamate uptake are similar to those observed for inhibition of GDH (all in the micromolar range -- see [Results](#S3){ref-type="sec"}). One concern is that the concentration of EGCG required to inhibit transport is approximately 500-fold higher than that required to inhibit GDH; one major difference is that the analyses of GDH were conducted with purified enzyme ([@B21]). Others have shown that the EGCG is not particularly stable in solution, is subject to active efflux from some cellular systems by ABC cassette proteins, and may be poorly absorbed across membranes ([@B29], [@B36]). Therefore, it is possible that this difference in potency simply reflects the fact that glutamate uptake was measured in an intact system. Based on analyses of crystal structures of GDH, HCP and BTH bind to distinct locations in the interior of the GDH hexamer ([@B30]). Based on analyses with epicatechin 3-monogallate (an EGCG analog), it seems that EGCG likely binds to the ADP-activation site, located by the pivot helix of GDH ([@B37]). We also considered the possibility that these compounds might block glutamate uptake through a direct interaction with GLT-1, but do not think this is likely for two different reasons. First, the fact that three different inhibitors have the same effect on uptake makes this a less likely explanation. Second, all three inhibitors block sodium-dependent GABA uptake as well, which is mediated by a completely distinct family of transporters that share no homology with the glutamate transporters \[for review, see ([@B38])\]. Therefore, we suggest that the simplest explanation for the present results is that inhibition of GDH rapidly inhibits Na^+^-dependent glutamate or GABA uptake.

In the present study, we found that inhibition of GDH had no effect on [l]{.smallcaps}-glutamate or [d]{.smallcaps}-aspartate transport in crude cerebellar membranes (P2) where GLAST likely mediates uptake ([@B20], [@B24], [@B32]). Yet, we previously found that EGCG inhibits glutamate uptake in astrocyte cultures ([@B19]) where uptake is also mediated by GLAST ([@B22], [@B23], [@B39]). These measures of transport were conducted in identical buffers; this suggests that the differential effects cannot be attributed to the utilization of different exogenous metabolites to generate ATP. Coupling of GDH to transport may vary depending on the maturation of the system; astrocytes in culture are polygonal, not stellate shaped as is observed *in vivo*, and do not express GLT-1 consistent with an immature phenotype ([@B22], [@B23]). While maturation may explain the difference between astrocytes in culture and crude cerebellar membranes (P2), GDH has been recently deleted from the CNS tissues in mice ([@B40]) and also been knocked down in astrocytes in culture ([@B41]). Interestingly, the mice with the CNS specific deletion of GDH display no overt behavioral phenotype, and one would predict a seizure phenotype if deletion of GDH resulted in impaired glutamate uptake *in vivo* ([@B42], [@B43]). Therefore, as has been observed with differential metabolism of glutamate in different systems or with increased neuronal activity \[for reviews, see ([@B44], [@B45])\], it seems likely that redundant systems may be differentially engaged to support glutamate uptake.

In the present study, we used crude membranes (P2). Previous studies have demonstrated that the pharmacology of glutamate uptake in cortical crude membranes parallels that observed for GLT-1 and is distinct from that observed in cerebellar crude membranes uptake ([@B20], [@B24], [@B32]). Furthermore, genetic deletion of GLT-1 reduces glutamate uptake in cortical crude membranes to 5% of control ([@B9]). These studies provide compelling evidence that uptake measured in cortical crude membranes is mediated by GLT-1 and that uptake measured in cerebellar crude membranes is mediated by GLAST. We examined the abundance of a neuronal membrane protein, the NR1 subunit of the NMDA receptor, and two glial membrane proteins, GLT-1 and GLAST in this membrane preparation. As was previously observed ([@B25], [@B26]), we found that this fraction contains high levels of neuronal and glial membrane proteins. We also found low levels of the cytoskeletal proteins, GFAP and NF-L. The absence of large amounts of either cytoskeletal protein suggests that the membranes do not uniformly reseal into vesicles and that the resealed vesicles contain only a small fraction of the original cytosol. This conclusion is also supported by the observation that cortical and cerebellar crude membranes contain comparable levels of GLT-1 (Figure [1](#F1){ref-type="fig"}), even though no GLT-1-mediated uptake is detected in cerebellar crude membranes (see above).

GLT-1 expression, when analyzed using immunohistochemical approaches ([@B7], [@B15], [@B16]), *in situ* hybridization of mRNA \[([@B46], [@B47]), and for reviews, see ([@B4], [@B5])\], or bacterial artificial chromosome GLT-1 promoter reporter mice ([@B48]), is essentially restricted to astrocytes. However, there is also evidence that GLT-1 is expressed in some neurons in the CNS ([@B8], [@B47], [@B49]). The P2 membrane preparation has also been used to examine the relative contributions of the different GABA transporters to uptake. The pharmacology of GABA transport in crude membranes (P2) is consistent with GAT-1 ([@B50], [@B51]), which is thought to be localized predominantly in neurons, but is also found in astrocytes \[for review, see ([@B52])\]. Although GLT-1 is heavily enriched in astrocytes and GAT-1 is enriched in neurons, it is not possible to determine if the effects of inhibition of GDH are related to inhibition of neuronal or glial pools of this enzyme. This will need to be a topic of further investigation.

Glutamate dehydrogenase is a mitochondrial enzyme that catalyzes the reversible deamination of glutamate to α-ketoglutarate \[for reviews, see ([@B53], [@B54])\]. This reaction is accompanied by the production of NADH that can be used to generate ATP; the downstream metabolism of α-ketoglutarate through the tricarboxylic acid cycle will also generate ATP. Cytoplasmic glutamate moves into mitochondria by one of two different families of transporters; neither of these processes transport [d]{.smallcaps}-aspartate ([@B55], [@B56]). Furthermore, GDH does not metabolize [d]{.smallcaps}-Asp ([@B33]). Therefore, although it is theoretically possible that GDH might support inward transport by rapidly metabolizing glutamate and thereby maintaining a concentration gradient, this is unlikely because inhibition of GDH also blocks transport of [d]{.smallcaps}-\[^3^H\]-Asp. Others have found that synaptosomes enriched from P2 contain relatively high levels of endogenous glutamate ([@B57]); therefore, it seems certain that the crude membranes (P2) used in the present study contain endogenous glutamate. Combined with the fact that these inhibitors also block GABA transport, these observations suggest that mitochondrial GDH provides energy for transport using endogenous glutamate to drive the Na^+^-dependent transport systems.

Several studies have demonstrated that inhibition of mitochondrial function impairs glutamate uptake. For example, the mitochondrial poisons, sodium azide, dinitrophenol, and antimycin A, inhibit glutamate uptake in cultured astrocytes ([@B58]). In addition, MPP^+^ and rotenone, inhibitors of complex 1 of the electron transport chain, inhibit glutamate clearance in both astrocytes and crude cerebral synaptosomes ([@B59], [@B60]). Opening mitochondrial K~ATP~ channels can functionally support glutamate uptake in the presence of MPP^+^ ([@B61]). There is also evidence that glutamate transport couples to ionic changes in mitochondria. In fact, uptake is accompanied by an increase in mitochondrial Na^+^ ([@B62]). Uptake is also accompanied by acidification of mitochondria ([@B63]). This may be dependent upon the mitochondrial glutamate--aspartate exchanger, Aralar, which co-transports a H^+^ with glutamate ([@B55]), or the mitochondrial glutamate carrier, which transports glutamate with a H^+^ or in exchange for a hydroxyl ion ([@B56]). The fact that inhibitors of GDH block glutamate uptake provides further support for a functional interaction between transporters and mitochondria.

Epigallocatechin-monogallate is considered the most active of the green tea polyphenols, the likely active ingredients in green tea; the effects of EGCG on biological/pathological processes have been examined in numerous *in vitro* and *in vivo* studies. EGCG is of particular interest in the treatment of Alzheimer's and Parkinson's diseases because it exhibits neuroprotective effects such as radical scavenging, iron chelating, activation of PKC, and anti-apoptotic action \[for review, see ([@B64])\]. *In vivo* studies have demonstrated the neuroprotective properties of EGCG. For example, these polyphenols improve spatial learning in aged rodents ([@B65]), they suppress peripheral nerve degeneration associated with sciatic nerve crush ([@B66]), and EGCG protects against hippocampal neuronal damage after global ischemia ([@B67]). *In vitro*, EGCG is protective at low concentrations, but at concentrations similar to those used in the present study, EGCG causes cell death in a neuroblastoma cell line ([@B68]). EGCG increases the amount of glutamate observed in the effluent upon depolarization of synaptosomes ([@B69]). In pancreatic β-cells, EGCG inhibits the increase in insulin secretion and glutamine oxidation caused by the stimulation of GDH ([@B21]). In most of these examples, it is unclear if the observed effects are related to inhibition of GDH or to the anti-oxidant activity of EGCG. Inhibition of GDH and glutamate uptake might contribute to some of the observed *in vivo* effects, but this will need to be resolved in future studies.

In summary, we show evidence that inhibition of the mitochondrial enzyme, GDH, can result in inhibition of Na^+^-dependent [l]{.smallcaps}-glutamate or [d]{.smallcaps}-aspartate uptake in mammalian cortex. It seems likely that this dependence on GDH is affected by factors that are yet to be defined.
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